Lupin gets Health Canada nod for arthritis drug

13 Sep 2022 , 02:18 PM

Rymti is Lupins biosimilar etanercept approved for all indications of the reference product Enbrel. It is available as an injectable easy-to-use pre-filled pen and a pre-filled syringe. Rymti is indicated in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (including ankylosing spondylitis and non-radiographic axial spondyloarthritis), plaque psoriasis and paediatric plaque psoriasis. Dr. Cyrus Karkaria, President at Lupin Biotech said, ?The approval for Rymti in Canada is a key milestone in our endeavors to improving access to medicines. It underscores the scientific success of Lupins biosimilar programs and our commitment to advancing healthcare through innovation.? Dr. Sofia Mumtaz, President of legal & compliance and Canada, Australia, and Japan said, ?We believe biosimilars will provide more Canadians with access to quality treatment, while reducing healthcare costs.? Lupin is an innovation-led transnational pharmaceutical company. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The drug maker reported a net loss of Rs 89.1 crore in Q1 FY23 as against a net profit of Rs 542.5 crore in Q1 FY22. Total revenue from operations declined 12.3% YoY to Rs 3,743.8 crore during the quarter. Shares of Lupin rose 0.29% to Rs 673.50 on the BSE. Powered by Capital Market – Live News